The COX-2 selective inhibitor celecoxib is currently being studied in a phase II trial as a possible therapeutic strategy for the treatment of HLA-A2+ refractory melanoma in combination with autologous alpha-type-1 polarized dendritic cells (alphaDC1)/TBVA cell-based treatment, rintatolimod, and recombinant interferon alpha-2 [41]. The gene discussed is PTGS2; the disease is melanoma.